Resistance Mechanisms to AZD9291 and Rociletinib-Letter

Clin Cancer Res. 2017 Jul 15;23(14):3966. doi: 10.1158/1078-0432.CCR-17-0167.

Nele Van Der Steen^{1

2

3}, Christian Rolfo^{1

4}, Patrick Pauwels^{1

2}, Adrianus J de Langen⁵, Godefridus J Peters³, Elisa Giovannetti^{6

7}

¹ Center for Oncological Research, University of Antwerp, Antwerp, Belgium.
² Department of Pathology, Antwerp University Hospital, Antwerp, Belgium.
³ Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands.
⁴ Phase I - Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Antwerp, Belgium.
⁵ Department of Respiratory Diseases, VU University Medical Center, Amsterdam, the Netherlands.
⁶ Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands. e.giovannetti@vumc.nl.
⁷ Cancer Pharmacology Lab, AIRC Start-Up Unit, University of Pisa, Pisa, Italy.

No abstract available

Publication types